Metraipolis › archive › dc_f4beaf9dbc6b

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial — Europe PMC PMID:42249138

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42249138
DOI
10.1038/s41591-[numero omesso]-6
License (as archived)
solo-consultazione
Archived
2026-10-31T18:21:27.264Z
SHA-256 of the archived text
c3a7c5c27ef982237896343cce7eb735578c72eccce68aeeca9186cbe69c200d
Stable URL of this page
https://metraipolis.com/documento/dc_f4beaf9dbc6b

How to cite

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial — Europe PMC PMID:42249138 — Europe PMC (en), https://europepmc.org/article/MED/42249138 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f4beaf9dbc6b (Metraipolis archive dc_f4beaf9dbc6b, sha256 c3a7c5c27ef982237896343cce7eb735578c72eccce68aeeca9186cbe69c200d)
BibTeX
@misc{dcf4beaf9dbc6b,
  title = {Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial — Europe PMC PMID:42249138},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42249138},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f4beaf9dbc6b; sha256 c3a7c5c27ef982237896343cce7eb735578c72eccce68aeeca9186cbe69c200d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42249138. Agents can read the archived copy with the MCP tool read_document.